Search

Community Engagement Guidelines
Route 79 Upload
Events
Evento
Our Products & Pipeline
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027